home.aspx
 
EVENTS

eyeforpharma Awards 2019
EYEFORPHARMA AWARDS 2019
December 11-11, 2019
You’ll already know if you’re a winner: your patients are telling you. But now it’s time to be recognised by your peers and the wider healthcare community. The eyeforpharma awards are unique. They’re the only awards that focus exclusively on what matters - value for patients ...

BIOFIT 2019
BIOFIT 2019
December 10-11, 2019
With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming fro...

AgeneBio

AgeneBio, Inc., is an emerging pharmaceutical company dedicated to developing innovative therapeutics that prevent neurodegeneration and preserve and restore cognitive function for unserved patients battling amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia stage of Alzheimer’s disease, and other neurological and psychiatric diseases.

RELATED NEWS


Takeda has announced that its drug Trintellix (vortioxetine) has been approved by the Japanese Ministry of Health, Labour and Welfare for the treatment of depression and depressed state. Danish company Lundbeck discovered Trintellix, but since 2017 Lundbeck and Takeda have been collaborating on the development of the drug in Japan. The two companies extended the agreement in 2018 to include co-commercialisation of the drug in Japan following its approval. This approval was based upon a randomise...

READ MORE

Researchers have evaluated the features of pre-approval and post-approval clinical trials of drugs granted Accelerated Approval by the U.S Food and Drugs Administration (FDA). To understand how this pathway is implemented, researchers examined the pre-approval and post-approval clinical trials of drugs granted approval between 2009 and 2013. During that time, the FDA granted 22 drugs and ordered 38 post-approval studies to confirm the safety and efficacy of these drugs....

READ MORE

New research has found that artificial intelligence (AI) in the drug discovery market is projected to increase at a compound annual growth rate (CAGR) of 40.8 percent from 2019 to 2024. According to MarketsandMarkets™, AI in drug discovery has been worth $259 million this year but will grow to be worth $1,434 million by the end of the forecast period. Some of the factors that are expected to be responsible for this increase include a growing number of cross-industry collaborations and part...

READ MORE

In response to a petition from Koios Pharmaceuticals LLC, the United States Patent and Trademark Office (“PTO”) has instituted inter partes review of the sole Orange-Book listed patent protecting Rasuvo®—a high-cost rheumatoid arthritis treatment—from generic competition. The PTO will now review the validity of all twenty-two claims of U.S. Patent 8,664,231, and on multiple grounds. In reaching its decision, the PTO noted that it was “persuaded that there is a reasonable likelihood that Petition...

READ MORE

As criminal fraud investigations continue into former Theranos CEO Elizabeth Holmes and president Ramesh Balwani, further details are emerging in two documentaries about how the company hoodwinked doctors, patients, and investors with bogus and exaggerated claims about its diagnostic technology. Earlier this month a federal judge granted more time to investigators in the criminal fraud case against Holmes and Balwani after the implosion of Theranos over the last couple of years. Once a silicon v...

READ MORE

DNA-damaging agents, or "DDAs," make up the most widely used group of cancer drugs. Yet their therapeutic success has been curtailed by drug resistance either present in cancer cells from the disease onset or arising during treatment. Now, biologists at the University of California San Diego have discovered a new way of re-sensitizing drug-resistant human tumor cells to the potency of DDAs. UC San Diego Project Scientist Manqing Li, Professor Michael David, and their colleagues describ...

READ MORE

EVENTS

BIOFIT 2019
BIOFIT 2019
December 10-11, 2019
With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming fro...

SiriusDecisions 2019 Technology Exchange
SIRIUSDECISIONS 2019 TECHNOLOGY EXCHANGE
December 09-11, 2019
The drive for growth never ceases for b-to-b organizations, and more than ever technology is at the centre of enabling that progress. Gone are the days however when a disparate, disconnected set of platforms strewn across sales, marketing an product can serve the organization effectively. An aligned...